Sermorelin 10 mg
Also known as · GRF(1-29) · Geref®
Sermorelin is the 29-amino-acid N-terminal fragment of GHRH — the minimum sequence for full GH-releasing activity.
Chemistry quick-facts
- CAS
- 86168-78-7
- Formula
- C149H246N44O42S
- MW
- 3357.93 Da
- Length
- 29 aa
- Status
- Sermorelin was approved as Geref® for paediatric GH-deficiency evaluation; the commercial product was discontinued in 2008. No current approved indication. Research use only.
- Purity (HPLC)
- ≥ 99.0%
Mechanism of action
Classical GHRH-receptor agonism; short-acting pulsatile stimulus to pituitary GH release.
Research context
Sermorelin (GRF 1-29) represents the minimum active fragment of GHRH. It has a short plasma half-life (~12 minutes) and was historically approved as a diagnostic agent for GH-deficiency evaluation.
The commercial product (Geref) was discontinued in 2008 — not for safety reasons. Widely used in preclinical GH-axis research today.
Published studies
A non-exhaustive list of peer-reviewed studies referenced when curating this entry. Click through to the primary source for the full text.
- Walker RF (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical Interventions in Aging.
Reconstitution
- Solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- · Inject diluent slowly down the side of the vial onto the cake.
- · Swirl gently — do not shake.
- · Solution should be clear and colourless. Discard if not.
Storage
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life — sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
FAQ
Why was Geref discontinued?+
The withdrawal was commercial, not safety-related. More targeted GHRH analogues (tesamorelin) and alternative diagnostic approaches displaced the commercial indication.
This page summarises the research literature on Sermorelin 10 mg for in vitro laboratory investigation only. It is not medical advice, not a treatment recommendation, and not a substitute for a qualified physician. Material is sold for analytical chemistry and cell-culture research, not for human or veterinary administration.
- ResearchCJC-1295 no DAC 10 mg
CJC-1295 without DAC — short-acting modified GRF(1-29). Commonly used in preclinical GH-pulse research alongside ipamorelin.
- ResearchIpamorelin 10 mg
Ipamorelin is a selective ghrelin-receptor (GHSR) agonist. One of the cleanest pharmacological profiles in the growth-hormone-secretagogue class.
- ResearchTesamorelin 10 mg
Tesamorelin is an approved GHRH analogue. The research-grade form is used widely in GH-axis, lipid-metabolism, and hepatic-fat research.
- GlossaryGHRH
Growth hormone-releasing hormone, the hypothalamic peptide that triggers GH release.
- BiomarkerTSH 4.5 mIU/L
TSH at 4.5 mIU/L sits at the top edge of most printed reference ranges (typically 0.4–4.0). What that number indicates physiologically, why "high-normal" matters, and what the research literature looks at when this pattern appears.
- BiomarkerFree T3 low, TSH normal
Free T3 below the reference range with a normal TSH suggests your body isn't converting T4 into the active T3 hormone efficiently. The research literature on conversion problems and what they look like.